secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0001798749-23-000013
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aerovate reports FY2022 net loss of $51.5M; cash runway into H2 2025
--------------------------------------------------------------------

- Net loss of $51.5M for FY2022 vs $23.0M in FY2021; R&D expenses $38.6M (up from $15.0M).
- Cash, cash equivalents and investments $129.2M as of Dec 31, 2022; sufficient to fund operations into H2 2025.
- IMPAHCT Phase 2b/3 trial of AV-101 for PAH ongoing; topline data expected Q4 2023 or Q1 2024.
- Four patents issued in 2022; management team strengthened with four new SVPs.
- Board appointed Donald Santel; expanded IP portfolio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000179874923000013/0001798749-23-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000179874923000013/tmb-20230329x8k.htm
  HTML page:      https://secwatch.observer/filing/0001798749-23-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer